WT1 Peptid Vaccination in Carcinomas

Charité University Medicine Berlin logo

Charité University Medicine Berlin

Status and phase

Unknown
Phase 2

Conditions

WT1 Expressing Carcinoma

Treatments

Biological: WT1 126-134 peptide

Study type

Interventional

Funder types

Other

Identifiers

NCT00153608
HaemaCBFWT104
EU

Details and patient eligibility

About

In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Metastatic cancer, no standard treatment option
  • Resected cancer with minimal residual disease, no standard treatment option
  • WT-1 expression
  • HLA-A2

Exclusion criteria

Concurrent chemotherapy

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Central trial contact

Carmen Scheibenbogen, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems